Medical Research Council-ko ikertzaileekin lankidetzan egindako argitalpenak (45)

2024

  1. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis

    The Lancet Psychiatry, Vol. 11, Núm. 1, pp. 36-46

2023

  1. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

  2. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  3. Spanish and cross-cultural validation of the mind excessively wandering scale

    Frontiers in Psychology, Vol. 14

2022

  1. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

    BMC Medical Research Methodology, Vol. 22, Núm. 1

  2. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352

  3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

2021

  1. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

    Cancer Cell, Vol. 39, Núm. 2, pp. 257-275.e6

  2. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

  3. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2019

  1. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

    JAMA network open, Vol. 2, Núm. 9, pp. e1911750

  2. Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism

    Movement Disorders, Vol. 34, Núm. 10, pp. 1547-1561

2018

  1. Human plasma C3 is essential for the development of memory B, but not T, lymphocytes

    Journal of Allergy and Clinical Immunology, Vol. 141, Núm. 3, pp. 1151-1154.e14

  2. Microbial translocation does not drive immune activation in ugandan children infected with HIV

    Journal of Infectious Diseases, Vol. 219, Núm. 1, pp. 89-100

  3. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

    HIV Medicine, Vol. 19, Núm. 1, pp. e1-e42

  4. Semantic and phonological schema influence spoken word learning and overnight consolidation

    Quarterly Journal of Experimental Psychology, Vol. 71, Núm. 6, pp. 1469-1481

2017

  1. Activity-Dependent Gating of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican

    Neuron, Vol. 95, Núm. 3, pp. 639-655.e10

  2. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

    Annals of Oncology, Vol. 28, Núm. 4, pp. 711-717

2016

  1. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals

    Medicine (United States), Vol. 95, Núm. 41